Posttranslational modifications of lysine and evolving role in heart pathologies-Recent developments

Proteomics

Volumn 15, Issue 5-6, 2015, Pages 1164-1180

  Stastna, Miroslava ^a   Van Eyk, Jennifer E ^b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Heart pathologies; Lysine PTMs; Modified proteins; Neddylation; Sumoylation; Technology

Indexed keywords

CULLIN; LYSINE; NEDD8 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SIRTUIN 1; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOG 2; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; UNCLASSIFIED DRUG; VACM 1; ZINC FINGER PROTEIN; PROTEOME;

AMINO ACID SEQUENCE; HEART DISEASE; HUMAN; NEDDYLATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SUMOYLATION; UBIQUITINATION; ANIMAL; BOVINE; CELL CULTURE; CHEMISTRY; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM; MOLECULAR GENETICS; MOUSE; PATHOLOGY; RAT;

AMINO ACID SEQUENCE; ANIMALS; CATTLE; CELLS, CULTURED; HEART DISEASES; HUMANS; LYSINE; MICE; MOLECULAR SEQUENCE DATA; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; RATS;

EID: 84924750745     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400312     Document Type: Review

References (127)

1. Desterro, J. M., Rodriguez, M. S., Hay, R. T., SUMO-1 modification of IkBα inhibits NF-kB activation. Mol. Cell 1998, 2, 233-239.
2. Filtz, T. M., Vogel, W. K., Leid, M., Regulation of transcription factor activity by interconnected post-translational modifications. Trends Pharmacol. Sci. 2014, 35, 76-85.
3. Danielsen, J. M., Sylvestersen, K. B., Bekker-Jensen, S., Szklarczyk, D. et al., Mass spectrometric analysis of lysine ubiquitylation reveals promiskuity at site level. Mol. Cell. Proteomics 2011, 10, M110.003590.
4. Jones, J., Wu, K., Yang, Y, Guerrero, C. et al., A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J. Proteome Res. 2008, 7, 1274-1287.
5. Minguez, P., Parca, L., Diella, F., Mende, D. R. et al., Deciphering a global network of functionally associated post-translational modifications. Mol. Syst. Biol. 2012, 8, 599.
6. Minguez, P., Letunic, I., Parca, L., Bork, P., PTMcode: a database of known and predicted functional associations between post-translational modifications in proteins. Nucleic Acid Res. 2013, 41, D808-D815.
7. Goldstein, G., Scheid, M., Hammerling, U., Schlesinger, D. H. et al., Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc. Natl. Acad. Sci. USA 1975, 72, 11-15.
8. Willis, M. S., Patterson, C., Into the heart: the emerging role of the ubiquitin-proteasome system. J. Mol. Cell. Cardiol. 2006, 41, 567-579.
9. Wadosky, K. M., Willis, M. S., The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H515-H526.
10. Rougier, J. S., Albesa, M., Abriel, H., Ubiquitylation and SUMOylation of cardiac ion channels. J. Cardiovasc. Pharmacol. 2010, 56, 22-28.
11. Vertegaal, A. C., Uncovering ubiquitin and ubiquitin-like signaling networks. Chem. Rev. 2011, 111, 7923-7940.
12. Matunis, M. J., Coutavas, E., Blobel, G., A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135, 1457-1470.
13. Shen, Z., Pardington-Purtymun, P. E., Comeaux, J. C., Moyzis, R. K. et al., UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics 1996, 36, 271-279.
14. Kumar, S., Yoshida, Y., Noda, M., Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem. Biophys. Res. Commun. 1993, 195, 393-399.
15. Schimmel, J., Eifler, K., Sigurosson, J. O., Cuijpers, S. A. et al., Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol. Cell 2014, 53, 1053-1066.
16. Jentsch, S., Psakhye, I., Control of nuclear activities by substrate-selective and protein group SUMOylation. Annu. Rev. Genet. 2013, 47, 167-186.
17. Chen, L., Ma, Y., Qian, L., Wang, J., Sumoylation regulates nuclear localization and function of zinc finger transcription factor ZIC3. Biochim. Biophys. Acta 2013, 1833, 2725-2733.
18. Beketaev, I., Kim, E. Y., Zhang, Y., Yu, W. et al., Potentiation of Tbx5-mediated transactivation by SUMO conjugation and protein inhibitor of activated STAT1 (PIAS1). Int. J. Biochem. Cell Biol. 2014, 50, 82-92.
19. Ding, B., Sun, Y., Huang, J., Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J. Biol. Chem. 2012, 287, 14621-14630.
20. Le, N., Corsetti, J. P., Dehoff-Sparks, J. L., Sparks, C. E. et al., Reactive oxygen species, sumoylation, and endothelial inflammation. Int. J. Inflam. 2012, 2012, 678190.
21. Yang, W., Thompson, J. W., Wang, Z., Wang, L. et al., Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics. J. Proteome Res. 2012, 11, 1108-1117.
22. Alshareeda, A. T., Negm, O. H., Green, A. R., Nolan, C. et al., SUMOylation proteins in breast cancer. Breast Cancer Res. Treat. 2014, 144, 519-530.
23. Kho, C., Lee, A., Jeong, D., Oh, J. G. et al., SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011, 477, 601-605.
24. Van Itallie, C. M., Mitic, L. L., Anderson, J. M., SUMOylation of claudin-2. Ann. NY Acad. Sci. 2012, 1258, 60-64.
25. Droescher, M., Chaugule, V. K., Pichler, A., SUMO rules: regulatory concepts and their implication in neurologic functions. Neuromolecular Med. 2013, 15, 639-660.
26. Wang, J., Cardiac function and disease: emerging role of small ubiquitin-related modifier. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011, 3, 446-457.
27. Kim, E. Y., Chen, L., Ma, Y., Yu, W. et al., Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects. PLoS One 2011, 6, e20803.
28. Nadtochiy, S. M., Redman, E., Rahman, I., Brookes, P. S., Lysine deacetylation in ischaemic preconditioning: the role of SIRT. Cardiovasc. Res. 2011, 89, 643-649.
29. Chairatvit, K., Ngamkitidechakul, C., Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol. Cell. Biochem. 2007, 306, 163-169.
30. Xirodimas, D. P., Sundqvist, A., Nakamura, A., Shen, L. et al., Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep. 2008, 9, 280-286.
31. Larance, M., Kirkwood, K. J., Xirodimas, D. P., Lundberg, E. et al., Characterization of MRFAP1 turnover and interaction sdownstream of the NEDD8 pathway. Mol. Cell. Proteomics 2012, 11, M111.014407.
32. Chen, Y., Neve, R. L., Liu, H., Neddylation dysfunction in Alzheimer's disease. J. Cell. Mol. Med. 2012, 16, 2583-2591.
33. Wang, M., Medeiros, B. C., Erba, H. P., DeAngelo, D. J., Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin. Ther. Targets 2011, 15, 253-264.
34. Hsiao, H. H., Meulmeester, E., Frank, B. T., Melchior, F. et al., "ChopNSpice, " a mass spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-conjugated peptides. Mol. Cell. Proteomics 2009, 8, 2664-2675.
35. Su, H. L., Li, S. S., Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002, 296, 65-73.
36. Bayer, P., Arndt, A., Metzger, S., Mahajan, R. et al., Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 1998, 280, 275-286.
37. Wei, W., Yang, P., Pang, J., Zhang, S. et al., A stress-dependent SUMO4 sumoylation of its substrate proteins. Biochem. Biophys. Res. Commun. 2008, 375, 454-459.
38. Hecker, C. M., Rabiller, M., Haglund, K., Bayer, P. et al., Specification of SUMO1 and SUMO2- interacting motifs. J. Biol. Chem. 2006, 281, 16117-16127.
39. Costa, M. W., Lee, S., Furtado, M. M., Xin, L. et al., Complex SUMO-1 regulation of cardiac transcription factor Nkx2-5. PLoS One 2011, 6, e24812.
40. Spengler, M. L., Kurapatwinski, K., Black, A. R., Azizkhan-Clifford, J., SUMO-1 modification of human cytomegalovirus IE1/IE72. J. Virol. 2002, 76, 2990-2996.
41. Wang, Y., Dasso, M., SUMOylation and deSUMOylation at a glance. J. Cell Sci. 2009, 122, 4249-4252.
42. Flotho, A., Melchior, F., Sumoylation: a regulatory protein modification in health and disase. Annu. Rev. Biochem. 2013, 82, 357-385.
43. Gao, T., Liu, Z., Wang, Y., Cheng, H. et al., UUCD: a family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res. 2013, 41, D445-D451.
44. Barry, J., Lock, R. B., Small ubiquitin-related modifier-1: wrestling with protein regulation. Int. J. Biochem. Cell Biol. 2011, 43, 37-40.
45. Wang, J., Schwartz, R. J., Sumoylation and regulation of cardiac gene expression. Circ. Res. 2010, 107, 19-29.
46. Liu, Z., Cao, J., Gao, X., Zhou, Y. et al., CPLA 1.0: an integrated database of protein lysine acetylation. Nucleic Acids Res. 2011, 39, D1029-D1034.
47. Liu, Z., Wang, Y., Gao, T., Pan, Z. et al., CPLM: a database of protein lysine modifications. Nucleic Acid Res. 2014, 42, D531-D536.
48. Meyer, M., Schillinger, W., Pieske, B., Holubarsch, C. et al., Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995, 92, 778-784.
49. Byrne, M. J., Power, J. M., Preovolos, A., Mariani, J. A. et al., Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008, 15, 1550-1557.
50. Warren, S. A., Terada, R., Briggs, L. E., Cole-Jeffrey, C. T. et al., Differential role of Nkx2-5 in activation of the atrial natriuretic factor gene in the developing versus failing heart. Mol. Cell. Biol. 2011, 31, 4633-4645.
51. Wang, J., Zhang, H., Iyer, D., Feng, X. H. et al., Regulation of cardiac specific nkx2.5 gene activity by small ubiquitin-like modifier. J. Biol. Chem. 2008, 283, 23235-23243.
52. Mukhopadhyay, D., Dasso, M., Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 2007, 32, 286-296.
53. Kim, E. Y., Chen, L., Ma, Y., Yu, W. et al., Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction. J. Mol. Cell. Cardiol. 2012, 52, 638-649.
54. Suzuki, Y. J., Cell signaling pathways for the regulation of GATA4 transcription factor: implications for cell growth and apoptosis. Cell. Signal. 2011, 23, 1094-1099.
55. Perdomo, J., Jiang, X. M., Carter, D. R., Khachigian, L. M. et al., SUMOylation regulates the transcriptional repression activity of FOG-2 and its association with GATA-4. PLoS One 2012, 7, e50637.
56. Nadtochiy, S. M., Yao, H., McBurney, M. W., Gu, W. et al., SIRT1-mediated acute cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H1506-H1512.
57. Yang, Y., Fu, W., Chen, J., Olashaw, N. et al., SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat. Cell Biol. 2007, 9, 1253-1262.
58. Ja, L. Y., Castri, P., Bembry, J., Maric, D. et al., SUMOylation paticipates in induction of ischemic tolerance. J. Neurochem. 2009, 109, 257-267.
59. Thong, C., Morrison, A., Mattison, S., Qian, S. et al., Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress. FASEB J. 2013, 27, 4332-4342.
60. Chhin, B., Hatayama, M., Bozon, D., Oqawa, M. et al., Elucidation of penetrance variability of a ZIC3 mutation in a family with complex heart defects and functional analysis of ZIC3 mutations in the first zinc finger domain. Hum. Mutat. 2007, 28, 563-570.
61. Brown, D. D., Martz, S. N., Binder, O., Goetz, S. C. et al., Tbx5 and Tbx20 act synergistically to control vertebrate heart morphogenesis. Development 2005, 132, 553-563.
62. Bolte, C., Zhang, Y., Wang, I. C., Kalim, T. V. et al., Expression of Foxm1 transcription factor in cardiomyocytes is required for myocardial development. PLoS One 2011, 6, e22217.
63. Li, T., Evdokimov, E., Shen, R. F., Chao, C. C. et al., Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: a proteomic analysis. Proc. Natl. Acad. Sci. USA 2004, 101, 8551-8556.
64. Vertegaal, A. C., Ogg, S. C., Jaffray, E., Rodriguez, M. S. et al., A proteomic study of SUMO-2 target proteins. J. Biol. Chem. 2004, 279, 33791-33798.
65. Filosa, G., Barabino, S. M. L., Bachi, A., Proteomics strategies to identify SUMO targets and acceptor sites: a survey of RNA-binding proteins SUMOylation. Neuromol. Med. 2013, 15, 661-676.
66. Matic, I., Schimmel, J., Hendriks, I. A., van Santen, M. A. et al., Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell 2010, 39, 641-652.
67. Westman, B. J., Verheggen, C., Hutten, S., Lam, Y. W. et al., A proteomic screen for nucleolar SUMO targets shows SUMOylation modulates the function of Nop5/Nop58. Mol. Cell 2010, 39, 618-631.
68. Westman, B. J., Lamond, A. I., A role for SUMOylation in snoRNP biogenesis revealed by quantitative proteomics. Nucleus 2011, 2, 30-37.
69. Perides, G., Harter, C., Traub, P., Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers. J. Biol. Chem. 1987, 262, 13742-13749.
70. Wang, L., Zhang, J., Banerjee, S., Barnes, L. et al., Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget 2010, 1, 620-627.
71. Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T. et al., Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7, 7-16.
72. Wang, L., Banerjee, S., Differential PIAS3 expression in human malignancy. Oncol. Rep. 2004, 11, 1319-1324.
73. Challa, A. A., Stefanovic, B., A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol. Cell. Biol. 2011, 31, 3773-3789.
74. Challa, A. A., Vukmirovic, M., Blackmon, J., Stefanovic, B., Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. PLoS One 2012, 7, e42989.
75. Soares, I. N., Caetano, F. A., Pinder, J., Rodrigues, B. R. et al., Regulation of stress-inducible phosphoprotein 1 nuclear retention by protein inhibitor of activated STAT PIAS1. Mol. Cell. Proteomics 2013, 12, 3253-3270.
76. Lee, C. T., Graf, C., Mayer, F. J., Richter, S. M., Dynamics of the regulation of Hsp90 by co-chaperone Sti1. EMBO J. 2012, 31, 1518-1528.
77. Beraldo, F. H., Soares, I. N., Goncalves, D. F., Fan, J., Stress-inducible phosphoprotein 1 has unique cochaperone activity during development and regulates cellular response to ischemia via the prion protein. FASEB J. 2013, 27, 3594-3607.
78. Yang, W., Sheng, H., Warner, D. S., Paschen, W., Transient global cerebral ischemia induces a massive increase in protein sumoylation. J. Cereb. Blood Flow Metab. 2008, 28, 269-279.
79. Yang, W., Sheng, H., Homi, H. M., Warner, D. S. et al., Cerebral ischemia/stroke and small ubiquitin-like modifier (SUMO) conjugation-a new target for therapeutic intevention? J. Neurochem. 2008, 106, 989-999.
80. Zhang, F., Liu, C. L., Hu, B. R., Irreversible aggregation of protein synthesis machinery after focal brain ischemia. J. Neurochem. 2006, 98, 102-112.
81. Gattenlöhner, S., Waller, C., Ertl, G., Bültmann, B. D. et al., NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. Am. J. Pathol. 2003, 163, 1081-1090.
82. Adachi, A., Takahashi, T., Ogata, T., Imoto-Tsubakimoto, H. et al., NFAT5 regulates the canonical Wnt pathway and is required for cardiomyogenic differentiation. Biochem. Biophys. Res. Commun. 2012, 426, 317-323.
83. Cohen-Barak, O., Yi, Z., Hagiwara, N., Monzen, K. et al., Sox6 regulation of cardiac myocyte development. Nucleic Acids Res. 2003, 31, 5941-5948.
84. Montero, J. A., Giron, B., Arrechedera, H., Cheng, Y. C. et al., Expression of Sox8, Sox9 and Sox10 in the developing valves and autonomic nerves of the embryonic heart. Mech. Dev. 2002, 118, 199-202.
85. Yang, W., Sheng, H., Thompson, J. W., Zhao, S. et al., Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways. Stroke 2014, 45, 1115-1122.
86. Rog-Zielinska, E. A., Thompson, A., Kenyon, C. J., Brownstein, D. G. et al., Glucocorticoid receptor is required for foetal heart maturation. Hum. Mol. Genet. 2013, 22, 3269-3282.
87. Oakley, R. H., Ren, R., Cruz-Topete, D., Bird, G. S. et al., Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. Proc. Natl. Acad. Sci. USA 2013, 110, 17035-17040.
88. Bretes, H., Rouviere, J. O., Leger, T., Oeffinger, M. et al., Sumoylation of the THO complex regulates the biogenesis of a subset of mRNPs. Nucleic Acids Res. 2014, 42, 5043-5058.
89. Schimmel, J., Larsen, K. M., Matic, I., van Haagen, M. et al., The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol. Cell. Proteomics 2008, 7, 2107-2122.
90. Papouli, E., Chen, S., Davies, A. A., Huttner, D. et al., Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol. Cell 2005, 19, 123-133.
91. Yao, Q., Li, H., Liu, B. Q., Huang, X. Y. et al., SUMOylation-regulated protein phosphorylation, evidence from quantitative phosphoproteomics analyses. J. Biol. Chem. 2011, 286, 27342-27349.
92. Eom, G. H., Cho, Y. K., Ko, J. H., Shin, S. et al., Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation 2011, 123, 2392-2403.
93. Xu, Y. M., Huang, D. Y., Chiu, J. F., Lau, A. T., Post-translational modification of human heat shock factors and their functions: a recent update by proteomic approach. J. Proteome Res. 2012, 11, 2625-2634.
94. Sakamoto, M., Minamino, T., Toko, H., Kayama, Y. et al., Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy. Circ. Res. 2006, 99, 1411-1418.
95. Eriksson, M., Jokinen, E., Sistonen, L., Leppa, S., Heat shock factor 2 is activated during mouse heart development. Int. J. Dev. Biol. 2000, 44, 471-477.
96. Nakai, A., Tanabe, M., Kawazoe, Y., Inazawa, J. et al., HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. Mol. Cell. Biol. 1997, 17, 469-481.
97. Tatham, M. H., Rodriguez, M. S., Xirodimas, D. P., Hay, R. T., Detection of protein SUMOylation in vivo. Nat. Protoc. 2009, 4, 1363-1371.
98. Ren, J., Gao, X., Jin, C., Zhu, M. et al., Systematic study of protein sumoylation: development of a site-specific predictor of SUMOsp 2.0. Proteomics 2009, 9, 3409-3412.
99. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., Yates III, J. R., Improved identification of SUMO attachment sites using C-terminal SUMO mutants and tailored protease digestion strategies. J. Proteome Res. 2006, 5, 761-770.
100. Galisson, F., Mahrouche, L., Courcelles, M., Bonneil, E. et al., A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells. Mol. Cell. Proteomics 2011, 10, M110.004796.
101. Lamoliatte, F., Bonneil, E., Durette, C., Caron-Lizotte, O. et al., Targeted identification of SUMOylation sites in human proteins using affinity enrichment and paralog-specific reporter ions. Mol. Cell. Proteomics 2013, 12, 2536-2550.
102. Da Silva-Ferrada, E., Xolalpa, W., Lang, V., Aillet, F. et al., Analysis of SUMOylated proteins using SUMO-traps. Sci. Rep. 2013, 3, 1690.
103. Bruderer, R., Tatham, M. H., Plechanovova, A., Matic, I. et al., Purification and identification of endogenous polySUMO conjugates. EMBO Rep. 2011, 12, 142-148.
104. Rabut, G., Peter, M., Function and regulation of protein neddylation. EMBO Rep. 2008, 9, 969-976.
105. Xirodimas, D. P., Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem. Soc. Trans. 2008, 36, 802-806.
106. Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A. et al., The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010, 1, 708-716.
107. Duncan, K., Schafer, G., Vava, A., Parker, M. I. et al., Targeting neddylation in cancer therapy. Future Oncol. 2012, 8, 1461-1470.
108. Leidecker, O., Xirodimas, D. P., Isolation of NEDDylated proteins in human cells. Methods Mol. Biol. 2012, 832, 133-140.
109. Antenos, M., Casper, R. F., Brown, T. J., Interaction with Nedd8, a ubiquitin-like protein, enhances the transcriptional activity of the aryl hydrocarbon receptor. J. Biol. Chem. 2002, 277, 44028-44034.
110. Johnson, A. E., Le, I. P., Andresen, B. T., Stodola, J. et al., VACM-1/cul5 expression in vascular tissue in vivo is induced by water deprivation and its expression in vitro regulates aquaporin-1 concentrations. Cell Tissue Res. 2012, 349, 527-539.
111. Su, H., Li, J., Osinka, H., Li, F. et al., The COP9 signalosome is required for autophagy, proteasome-mediated proteolysis, and cardiomyocyte survival in adult mice. Circ. Heart Fail. 2013, 6, 1049-1057.
112. Kooij, V., Venkatraman, V., Tra, J., Kirk, J. A. et al., Sizing up models of heart failure: proteomics from flies to humans. Proteomics Clin. Appl. 2014, 8, 653-664.
113. Meehan, K. L., Holland, J. W., Dawkins, H. J., Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002, 50, 54-63.
114. Bennett, E. J., Rush, J., Gygi, S. P., Harper, J. W., Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell, 2010, 143, 951-965.
115. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J. et al., An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458, 732-736.
116. Nawrocki, S. T., Griffin, P., Kelly, K. R., Carew, J. S., MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin. Investig. Drugs 2012, 21, 1563-1573.
117. Brownell, J. E., Sintchak, M. D., Gavin, J. M., Liao, H. et al., Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 2010, 37, 102-111.
118. Bosu, D. R., Kipreos, E. T., Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div. 2008, 3, 7.
119. Lee, J. E., Sweredoski, M. J., Graham, R. L., Kolawa, N. J. et al., The steady-state repertoire of human SCF ubiquitin ligase complexes does not require ongoing Nedd8 conjugation. Mol. Cell. Proteomics 2011, 10, M110.006460.
120. Liao, H., Liu, X. J., Blank, J. L., Bouck, D. C. et al., Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol. Cell. Proteomics 2011, 10, M111.009183.
121. Zheng, Y., Kong, Y., Li, F., Krüppel-like transcriptional factor 11 (KLF11) overexpression inhibits cardiac hypertrophy and fibrosis in mice. Biochem. Biophys. Res. Commun. 2014, 443, 683-688.
122. Cullingford, T. E., Butler, M. J., Marshall, A. K., Tham, R. L. et al., Differential regulation of Krüppel-like factor family transcription factor expression in neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and cytokines. Biochim. Biophys. Acta 2008, 1783, 1229-1236.
123. Takeda, N., Manabe, I., Uchino, Y., Eguchi, K. et al., Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 2010, 120, 254-265.
124. Na, C. H., Jones, D. R., Yang, Y., Wang, X. et al., Synaptic protein ubiquitination in rat brain revealed by antibody-based ubiquitome analysis. J. Proteome Res. 2012, 11, 4722-4732.
125. Chen, Y., Liu, W., McPhie, D. L., Hassinger, L. et al., APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J. Cell Biol. 2003, 163, 27-33.
126. Tanskela, J. S., Chakravarthy, B. R., Murray, C. L., Wang, Y. et al., Evidence from cultured rat cortical neurons of differences in the mechanism of ischemic preconditioning of brain and heart. Brain Res. 1999, 827, 143-151.
127. Soler, E. P., Ruiz, V. C., Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. Curr. Cardiol. Rev. 2010, 6, 138-149.